ABSTRACT
Patients with newly diagnosed ovarian cancer oen present with widespread peritoneal disease. Griths was the rst to demonstrate the potential benet of surgical debulking in cases of advanced ovarian cancer. His initial study demonstrated a signicant survival benet for patients in whom residual disease could be minimized to less than 1.5 cm [1]. e traditional management for advanced epithelial ovarian, tubal, and peritoneal cancers has been to perform maximal cytoreductive surgery, with the intent to remove all large-volume disease. is led to the current denition of optimal cytoreduction-debulking to no remaining tumor nodule greater than 1 cm in maximal diameter [2]. However, this current concept of optimal debulking has been challenged recently as a growing body of literature has shown that complete gross resection to no visible residual disease is associated with the most favorable outcomes [3,4].
